Market Information
Asia Pacific

The Biotechnology Market in India

June 2002

Department of Foreign Affairs and International Trade
FaxLink #42587

Report prepared by the Market Research Centre
Market Support Division (TCM)
Department of Foreign Affairs and International Trade
125 Sussex Drive, Ottawa K1A 0G2
Fax: (613) 943-1103
E-mail: mrc@dfait-maeci.gc.ca

The Market Research Centre produces a wide range of market reports by region and sector for Canadian exporters. These reports are available from:
- DFAIT's InfoExport Internet site (http://www.infoexport.gc.ca).

The Government of Canada has prepared this report based on primary and secondary sources of information. Readers should take note that the Government of Canada does not guarantee the accuracy of any of the information contained in this report, nor does it necessarily endorse the organizations listed herein. Readers should independently verify the accuracy and reliability of the information.

Market Highlights 

• Biotechnology in India is an emerging industry with a highly educated community of scientists and researchers, strong government support and a growing infrastructure base. 
• There are as many as 800 companies active in the market; up to 50 of those companies work on advanced biotechnology applications.
• The industry was valued at $3.7 billion and is expected to grow to $6.7 billion by 2010.
• Approximately 60% of the industry is devoted to human health applications, 10% to agricultural biotechnology and 30% to industrial applications, bioinformatics and genomics.

Opportunities 

• Indian biotechnology companies have expertise in bioinformatics, manufacturing and genetics, as well as more traditional sectors of the industry including fermentation technology, industrial enzymes and vaccines.
• There are opportunities to partner with Indian companies at the drug discovery stage of research, and to use Indian companies for contract research and manufacturing.
• There are also opportunities to form joint-venture partnerships with Indian companies, or establish technology transfer agreements or strategic research partnerships with key research institutions.
• The Indian market represents opportunities to produce and sell vaccines and therapeutics that respond to the needs of the millions of poor in India.

Key Players 

• Key domestic players in the industry include Reliance Life Sciences, Dr. Reddy's Laboratory, Shantha Biotech, Panacea Biotech and Biocon.
• Multinational corporations are active in the market and control the majority of pharmaceutical and biopharmaceutical imports.

Export Checklist 

• Intellectual property rights in India are weak but improving. The regulatory system for biotechnology products is not completely transparent.

Market Summary

• The biotechnology industry¹ in India is an emerging industry with significant promise for growth. There is a solid base of expertise in the country and strong government support for the industry at both national and state levels. India has the largest number of English-speaking scientists in the world outside the United States, and a highly educated and skilled workforce.
• There are approximately 800 companies working in the biotechnology sector in India, with between 30 and 50 companies working on advanced biotechnology applications. Key areas of expertise include research and production of vaccines, diagnostics, enzymes and biopesticides.
• The industry was valued at $3.7 billion² in 2001 and employed approximately 20 000 people. Growth is expected to top $6.7 billion by 2010. Sales of biotechnology products for both human and animal healthcare totalled $115 million in 2000 and are expected to grow to almost $200 million by 2005.
• Approximately 60% of companies and research centres in the Indian biotechnology market work in health-related industries. Of the balance, 10% work in agriculture and 30% work in industrial applications, bioinformatics and genomics.
• The Indian biotechnology industry is focussed in the southern state of Karnataka (especially in Bangalore), with other clusters of activity in the states of West Bengal, Maharashtra, Andhra Pradesh, Hyderabad and Kerala. Bangalore is branding itself as a "biocity" and is promoting convergence and growth between its successful information technology industry and biotechnology-the result of which is a growing bioinformatics industry. All the states mentioned above are establishing tax incentive programs for biotechnology companies (domestic and international) and investing in the construction of biotechnology research parks.
• There are a large number of government-funded research institutions in India that have established a solid research base in biotechnology. The national government has invested more than $750 million in biotechnology since 1985.
• Both the federal and state governments are encouraging more jointly funded private and public research initiatives on commercially viable projects.
• Venture capital for biotechnology in India is limited but growing. ICICI Venture Funds Management Co. Ltd. is India's largest venture capital company. It announced the creation of the ICICI Biotechnology Incubator Fund in March 2002 with a target size of $32 million. The company has already invested in local industry leaders, including Biocon and Avesthagen.
• The Department of Biotechnology (DBT)³ has also announced venture funding for small and medium-sized biotechnology companies. While the size of the fund has not yet been announced, it will be part of the Technology Development Fund program.
• The DBT and the Indian Council of Agricultural Research (ICAR) have stressed the importance of government funded research and development for biotechnology and are requesting $560 million from the federal government for the tenth five-year plan. The DBT is seeking $90 million for 2002-2003, but has so far received $58 million. The budget will be used for ongoing programs in vaccine research, genomics, transgenic plants and animals, and technology transfer. The DBT is also looking to support state governments in building biotechnology parks and research centres.
• Particular strengths in the Indian biotechnology industry include expertise in pharmaceutical manufacturing and fermentation technologies, skills in handling microbes and animal cells, experience with plant and animal breeding, growing expertise in bioinformatics and solid infrastructure at numerous research centres.
• Challenges for the industry will be to focus publically funded research efforts on particular strengths, increase intellectual property protection and improve the regulatory systems for both medical and agricultural products. Critics accuse the government of supporting research in areas that have already been perfected in other parts of the world and of conducting unnecessary regulatory reviews of products already approved in Europe and North America. This "re-inventing the wheel" has slowed progress for product approvals and in niche sectors of research that are particular strengths for India, including bioinformatics, pharmacogenomics and seed research.
• The All India Biotechnology Association (AIBA) has called for revisions to the regulatory system to make it less bureaucratic and more transparent. The association claims that the system, as it now stands, does not encourage private-sector investment in the industry.

Medical Biotechnology/Pharmaceuticals

• In the biomedical and pharmaceutical field, the Indian biotechnology industry is dominated by generics manufacturers. Because of limited intellectual property protection in India-patents are issued on the process but not the product-companies are able to work backward from the finished product to develop new processes and launch a similar product. As a result, many biotechnology companies in India have limited experience with drug discovery and development. However, this is slowly changing as companies begin to look to the future and see how a strong intellectual property regime can have a positive effect on the way they do business.
• Given Indian strengths in producing generic medications, companies are looking to increase their capabilities in biotechnology processing and manufacturing in anticipation of a new series of biotechnology-based generic drugs. As drug patents on some of the earliest biotechnology drugs expire in the coming years, there will be a new market for biotechnology-based generics.
• The pharmaceutical market (both biotechnology-based pharmaceuticals and traditional pharmaceuticals) was estimated at $8 billion and is expected to grow to $37 billion by 2010. There are approximately 250 large, research-based pharmaceutical companies in India, with as many as 3000 companies active in pharmaceutical (particularly generics) manufacturing. The industry employsapproximately 460 000 people and is the world's fifth-largest producer of medications by volume.
• The Indian biotechnology industry is ranked third in the world in terms of stem cell research, primarily because both the government and private industry have invested heavily in research institutes studying human disease and searching for treatments. As well, the issues of embryonic stem cell research have not generated the same moral debate in India as they have in Canada, the United States, Britain and other countries. In fact, a bioethics committee has determined that human embryonic stem cells may be harvested, with full and informed consent from the donor, up to the 14th day of gestation.
• Two research laboratories-the National Centre for Biological Sciences (NCBS) in Bangalore and Reliance Life Sciences-have been identified by the United States Institutes of Health Research as having cutting-edge embryonic stem cell research. Ten stem cell lines are eligible for funding under new guidelines in the United States restricting the use and application of embryonic stem cells. A total of 64 stem cell lines around the world have been identified.
• Despite the advanced work in stem cell research, India has not yet formulated a policy on human cloning. The government has decided to study the issue more closely and does not feel there is a need to rush because the capacity to clone a human does not currently exist in India.
• The vaccine market in India, valued at approximately $150 million, is a key component of the biomedical sector. The first biotechnology-based vaccine released in the Indian market was an rDNA hepatitis B vaccine produced by Shantha Biotechnics Pvt Ltd. Other biotechnology medications on the market include recombinant insulin, human growth hormone, alpha interferon, blood clotting factor VIII and medical proteins such as relaxin, rennin and interleukins.
• The diagnostics market is valued at an estimated $75 million and is dominated by demand for monoclonal and polyclonal antibodies, tissue typing, clinical assays and contract research.
• The Indian biotechnology industry is becoming an international hub for contract research and manufacturing. With a high level of expertise, low research and development costs and attractive incentives, many large pharmaceutical and biotechnology companies are establishing agreements with India companies and research institutions.
• Small Indian biotechnology companies are currently focussed on contract research as a way to build capacity prior to establishing drug discovery divisions.

Agricultural Biotechnology

• More and more companies are interested in the agricultural biotechnology sector in India because there are perceived to be fewer government restrictions and financial investments are not as heavy. However, lack of a strong regulatory infrastructure, limited subsidies available and ignorance on the part of many farmers about the benefits of genetically modified (GM) seeds has delayed growth of the industry.
• India is the world's largest producer of fruits and vegetables, but only accounts for 1% of total world exports. Indian agriculture is often inefficient and plagued by pests. The potential of agricultural biotechnology to feed the people of India and increase export markets for Indian products is significant.
• India is the world's third-largest cotton producer in terms of area, but with yields of approximately 300 kg per hectare, the country produces far below the global average of 650 kg per hectare.
• To date, only a small number of companies and research institutions have been allowed to conduct field trials on GM crops. Trials have been (and are currently) conducted on rice, maize, cotton, tomatoes and cauliflower.
• In 2001, approximately 4000 hectares of GM cotton were found to be growing illegally and were ordered destroyed.
• U.S.-based multinational Monsanto has partnered with Maharashtra Hybrid Seed Company Ltd (Mahyco) to research and produce a genetically engineered cotton for the Indian market.
• In March 2002, India's Genetic Engineering Approval Committee approved the commercial release of 3 Bt cotton hybrids that are genetically engineered to be insect resistant (a fourth is still in field trials and likely to be approved before the end of 2002). Five years of field trials were conducted by Mahyco prior to receiving approval.
• Conditions for the three-year approval period include the stipulation that fields of Bt cotton must have a surrounding planting, or refuge, of the same non-Bt variety that is at least five rows deep or 20% of the total areas sown in GM cotton. As well, the seeds may only be sold in specific areas of the country and must adhere to certain labelling and packaging instructions.
• Experts predict as much as 150 000 hectares of the new GM varieties will be planted in the first year.
• The move to approve GM cotton has seen some resistance from the Communist Party of India as well as environmental groups and other non-governmental organizations. In general, however, the Indian people are receptive to the new crop, particularly because it is not intended for consumption and the potential benefits to the cotton and related textile industries are enormous.
• The biotechnology industry also holds potential for the Indian textile industry with the development of novel fibres, improved processing methods and more effective and environmentally friendly dyes.
• Now that the first GM product has been approved for commercial release, India is expected to approve other crops, including mustard, soybeans, corn and potatoes, in the near future.
• Focus areas for future growth in agricultural biotechnology in India will be biofertilizers and biopesticides.
• There is also market demand in India for biotechnology-based animal health products including vaccines, diagnostics and technologically advanced animal feed.

Government Support

• Both the national and state governments in India are strong supporters of biotechnology growth.
• The focal point for biotechnology within the national government is the Department of Biotechnology. The DBT is active on various levels, from providing support for government-funded research centres, to working with various advisory committees to formulate India's biotechnology policy. Complete details of all programs and activities are available on line at http://dbtindia.nic.in.

Various components of the department include:

• the Scientific Advisory Committee for DBT (SAC-DBT), which advises the DBT on policy issues, new developments in the industry, and implementation and monitoring of new technologies;
• the DBT-ICAR, a joint committee of the DBT and the Ministry of Agriculture's Indian Council of Agricultural Research, which supports growth and development in the agricultural biotechnology field;
• the recombinant DNA Advisory Committee (RDAC), which is responsible for establishing, reviewing and updating biosafety guidelines;
• Institutional Biosafety Committees (IBSC), which implement and enforce biosafety guidelines on specific projects within research centres, universities and other national laboratories; and
• the Review Committee of Genetic Manipulation (RCGM), which authorizes containment conditions for experiments, closed trials and small-scale field trials, and monitors those trials to ensure safety standards are met. The RCGM also approves import requests for products needed for experimental work/training and research, such as etiologic agents and vectors, germ plasmas, or organelle, etc.
• The Ministry of the Environment and Forests is also responsible for sections of India's biotechnology regulatory system. Specifically, the Genetic Engineering Approval Committee (GEAC) regulates large-scale trials and environmental release of all GM organisms, as well as all imports and exports of GMOs. GEAC issues licences after reviewing all the necessary studies of closed trials, environmental safety studies and other supporting documents.
• In January 2002, the DBT articulated priority research areas for government funding in biotechnology. These areas include vaccines based on genomic research for cholera, malaria, AIDS, rabies and tuberculosis as well as biofertilizers, biopesticides, transgenic crops, and gene therapy for cancer treatment. A biotechnology vision document release in late 2001 outlines additional plans over the next 10 years and includes developing edible vaccines for specific disease targets, testing and approving a series of GM crops, developing additional vaccines and diagnostic tools for major communicable diseases, as well identifying and protecting biodiversity "hot spots."
• The Indian government has entered into a number of biotechnology co-operation agreements in an effort to foster additional growth in this sector. For example, India and Mauritius have signed an agreement to co-operate in the field of agriculture and crop management. The Memorandum of Understanding includes exchange provisions for scientists and students and research co-operation in such areas as plant breeding and crop improvement using biotechnology, genome mapping and bioinformatics, vaccines and plant variety protection. 
• India also has a biotechnology co-operation agreement with Indonesia to collaborate in the production of inexpensive medications and vaccines. The agreement also includes provisions for research exchange and training opportunities for scientists.
• India and Russia announced the creation of a joint centre of excellence in biotechnology in Allahabad at the Indian Institute of Information Technology. The DBT and the Russian Academy of Sciences will both fund and co-ordinate research activities related to food, nutrition and bioinformatics.

Key Research Centres

• The National Centre for Biological Sciences (NCBS) in Bangalore is owned by the Tata Institute of Fundamental Research, which was founded by the industrial firm Tata. The NCBS has three potential stem cell lines that meet U.S. funding requirements for embryonic stem cell research. The centre has not yet decided, however, if it will collaborate with the United States in this field.
• The Tata Energy Research Institute (TERI) works in the field of agricultural biotechnology and is currently researching GM mustard, forestry applications for biotechnology, microbes for bioremediation, biopesticides and biofertilizers.
• The Indian Council of Medical Research (ICMR) is the focal point for all medical and human health-related biotechnology research in India. The ICMR is funded through the Ministry of Health and includes 21 permanent research centres and institutes, six regional medical research centres, and a series of Centres for Advanced Research based on existing expertise and infrastructure at educational centres and other research institutes across the country. The ICMP also offers grant and scholarship funding for specific projects and conducts task force-based studies on time-sensitive projects.
• ICMR recently received $30 million over five years from the Ministry of Health for genomics, stem cell and structural biology research. The funding will be divided among various research centres and medical institutions under the direction of ICMR.
• The Indian Council of Agricultural Research is the focal point for agricultural research in Indian, including agricultural biotechnology. ICAR co-ordinates research, education, training, international partnerships and technology transfer. Its infrastructure includes 46 central research institutes, 10 project directorates, 27 national research centres, 90 co-ordinated research projects and 261 Krishi Vigyan Kendras (technical/vocational training and practical research centres).
• The Council of Scientific and Industrial Research (CSIR) has a series of 40 laboratories throughout India covering all areas of scientific research. Biotechnology applications are found at the Central Drug Research Institute, the Central Food Technologies Research Institute, the Centre for Cellular and Molecular Biology, the Industrial Toxicology Research Centre and the Indian Institute of Chemical Biology.
• The Centre for Cellular and Molecular Biology (CCMB) is focussed on research and applications of modern biology. The CCMB aids in the development of biotechnology in India through basic and applied research, training, and industry collaborations and acts as an information source for biological and biotechnology research. Key research areas include gene therapy, genomics, drug delivery systems, and the use of DNA chips in disease diagnosis. The CCMB was involved in developing the rDNA-based hepatitis-B vaccine now manufactured and sold by Shantha Biotechnics Ltd., and has worked with other companies to transfer technology or assist with collaborative research efforts.

Opportunities

• Key players in the biotechnology industry predict the Indian biotechnology market will grow substantially after 2005 as a result of stronger intellectual property protection (see Export Checklist below). Companies currently active in the market are cautious when transferring technology and often sign confidentiality agreements with partner companies. Canadian companies who enter the Indian market early stand to benefit from increased growth and opportunities after 2005. Early entry and a solid foundation in the market will benefit those able to work within the current limitations of intellectual property protection.
• Biotechnology and pharmaceutical companies in India are looking to market their expertise in bioinformatics, manufacturing and pharmacogenomics to form partnerships and alliances with drug discovery companies. The emphasis on drug discovery is just beginning in India; however, companies have other skills to offer Canadian companies interested in this market.
• There are opportunities to collaborate with and sell products and services to Indian companies already established in biotechnology subsectors, including industrial enzymes and biopesticides. Canadian companies with expertise in these fields will find a high level of interest among Indian companies.
• India provides opportunities for Canadian companies to employ Indian partners as contract researchers. There is a large pool of scientific talent in the country and infrastructure costs are low when compared to North America or Europe. Capacity exists for work on monoclonals, synthetic peptides and recombinant antigens. There are also opportunities to make use of Indian's vast and varied population for clinical trial and pharmacogenomics studies. The Indian industry recognizes the value of the country's biodiversity, and also the diversity of its people for genetic research.
• There are opportunities to produce and sell vaccines and therapeutics that respond to the needs of the millions of poor in India. Simple, effective and lowcost treatments for diarrheal diseases, influenza, tuberculosis, malaria, meningitis and pneumonia will find a ready market in India. As well, the market for diagnostics is also significant. Demand will increase for immunodiagnostics for tuberculosis, typhoid, malaria and other microbial infections.
• MDS Sciex, a Canadian company specializing in mass spectrometry, established a partnership in January 2001 with Kshema Technologies, a software development company, to establish a research chair in bioinformatics at the People's Education Society Institute of Technology (PESIT) in Bangalore.

Key Players

• Key domestic players in the Indian biotechnology industry include Reliance Life Sciences, Dr. Reddy's Laboratory, Shantha Biotech, Panacea Biotech and Biocon.
• Multinational corporations, including GlaxoSmithKline (U.K.), Novartis (Switzerland), Eli Lilly (U.S.), Pfizer (U.S.), Monsanto (U.S.) and Aventis (France) are all active in the Indian market. Companies typically partner with a local player. Pfizer and Bayer (Germany) are seeking to establish wholly owned manufacturing and marketing companies in India.
• The new pharmaceutical policy announced by the Government of India in February 2002 allows up to 100% foreign investment in all areas of the pharmaceutical industry except bulk drugs produced by the use of recombinant DNA technology, bulk drugs requiring in-vivo use of nucleic acids, and specific cell/tissue targeted formulations. Further details on this policy may be obtained from: http://www.techno-preneur.net/timeis/cgovt/pharmapolicy.html.

Company Activities

• Dabur India Ltd. announced in April 2002 that it has established a molecular diagnostic laboratory at the Rajiv Gandhi Cancer Institute and Research Centre in New Delhi with plans for additional facilities in Mumbai, Ahmedabad and Chennai. The laboratories will use genomic and proteomic profiling to detect molecular changes in cancer patients. The company also manufactures and sells 22 anti-cancer drugs in India.
• Reliance Life Sciences, part of Reliance Industries, has begun design and construction of a life sciences complex in Mumbai. The site will include research laboratories, green houses and pilot manufacturing facilities. Some of the laboratories will be built in 2002 and the entire complex is expected to be complete in 2003. The company is active in areas of stem cell research, as well as medical, plant and industrial biotechnology.
• Seven embryonic stem cell lines created by Reliance Life Sciences are eligible for U.S. funding.
• As well as stem cell research, the company has announced plans to establish a repository of blood drawn from umbilical cords (which also contain stem cells), and to establish manufacturing facilities to make artificial skin for burn victims.

• Sartorius, an Indian bioengineering company, is planning to establish an incubator and knowledge centre in Bangalore to provide training, support for process scale-up, production for clinical trials, lab services, contract manufacturing, and other support services.
• Strand Genomics Pvt. Ltd., announced in January 2002 that it has licensed software that classifies images in a three-dimensional structural analysis to a U.S.-based company.
• Biocon (Bangalore), India's largest biotechnology company, began operations in the late 1970s and manufactured enzymes to break down the pectin in fruit juice. The company has continued to work in the area of fermentation technology and has developed state-of-the-art technology to manufacture a group of cholesterollowering drugs. Biocon has also begun development of genetically engineered medications, including anti-infectives.
• Shantha Biotechnics Pvt Ltd. is a vaccine production company that has produced and successfully marketed a genetically modified, hepatitis-B vaccine in India. In April 2002, Shantha Biotechnics and Biocon announced a joint venture to manufacture and sell recombinant human insulin. The global patent on recombinant human insulin expires in 2003 and the two companies have formed this partnership to ensure a place in the market once the patent expires.
• Bangalore Genei, based in Bangalore, produces restriction enzymes, DNA polymerases and modifying enzymes-all critical tools for genomic research. Prior to establishing operations, these research tools were all imported by Indian companies and research centres. The company controls 30% of the Indian market for these products.
• Dr. Reddy's Laboratory is a long-standing pharmaceutical company that has recently added a biotechnology division. The company has a licensing agreement with Novo Nordisk for diabetes therapeutic technology and is developing human therapeutic proteins through rDNA technology.
• Avesthagen Graine is a small biotechnology company focussed on applications of plant molecular biology including genome sequencing (Basmati rice), plant transformations, marker-aided selection and proteomics. Revenue is generated through contract research and the company plans to develop intellectual property to licence to local and international companies.
• Panacea Biotech Ltd., a pharmaceutical company based in Delhi, will produce and market a vaccine for anthrax developed jointly by the Centre for Biotechnology at Jawaharlal Nehru University and the Department of Biotechnology. The drug is expected to receive fast-track approval through the regulatory system (see Export Checklist below).

Export Checklist

Intellectual Property

• Intellectual property rights in India are a primary concern and are one of the main limiting factors for growth in the biotechnology industry. India has only been a recent participant in World Trade Organization regulations for patent protection and intellectual property rights. The current system in India allows a seven-year patent on processes and not the end result. Companies are, therefore, able to study the end product and produce it using an unpatented processing method.
• Indian copyright legislation is considered strong; however, enforcement is poor and piracy is rampant.
• A full spectrum of intellectual property rights is expected to come into force in 2005.

Regulatory Issues

• The regulatory system in India for biotechnology products has been criticized by the All India Biotechnology Association for being bureaucratic and secretive. The AIBA has called for revisions as a way to stimulate additional growth in the industry and has proposed a single national regulatory agency for all biotechnology products under direct authority from the prime minister and independent of various government departments and ministries.
• Currently, biotechnology products must be reviewed by both district and state monitoring committees. Products are then reviewed by committees at the national level, including from the DBT, the Department of Health, the Ministry of Agriculture and the Ministry of Environment.

Medical Biotechnology/Pharmaceuticals

All pharmaceutical products, including biopharmaceuticals, must receive approval from the Drug Controller General of India (DCGI) prior to sale in India. The New Drug Application must be forwarded with all necessary information and, in general, phase III clinical trails must be conducted in India before approval is given. If a product has not received marketing approval in other countries, some phase II trails may be required, but the drug is not likely to be approved for sale in India until it is approved in the country of origin.

• There are some fast-track approval processes for drugs approved abroad and in desperate demand in India.
• The National Pharmaceutical Pricing Authority is responsible for setting prices on all new drugs in the Indian market.
• Companies seeking to manufacture pharmaceuticals in India must acquire a licence from the central government. Small companies with investments of less than Rs 7.5 million ($250,000) must obtain a licence from the state health authority.

Agricultural Biotechnology

• Agricultural biotechnology products must first be approved by a local Institutional Biosafety Committee (there are more than 160 throughout India). The group of experts will review any potential toxicity, allergenicity and environmental biosafety issues. Once the project is ready to leave the laboratory, small-scale containment experiments must be approved by the Review Committee on Genetic Manipulation (RCGM) within the DBT. The Monitoring cum Evaluation Committee will visit test sites to ensure compliance with regulations and present any reports to the RCGM. The final layer of approvals is from the Genetic Engineering Approval Committee (GEAC), which approves large-scale field trials and eventual commercial release.

Key Contacts

Canadian Government Contacts

Canadian High Commission in India
PO Box 5208, Chanakyapuri
New Delhi, 110021 India
Tel.: (91-11) 687-6500
Fax: (91-11) 687-5387
E-mail: delhi.commerce@dfait-maeci.gc.ca
Internet: http://www.infoexport.gc.ca/in

Canadian Government Trade Office in Bangalore
103 Prestige Meridian 1, First Floor, Rear Wing
29 M.G. Road
Bangalore, 560001 India
Tel.: (91-80) 559-9418
Fax: (91-80) 559-9424
Contact: D.P. Vittal Nath, Trade Advisor and Commercial Officer
E-mail: maple@blr.vsnl.net.in
Internet: http://www.infoexport.gc.ca/in

Office of the High Commission in Chandigarh
SCO no. 33-35, Sector 17-A
Chandigarh, 160017 India
Tel.: (91-172) 716-020-24
Fax: (91-172) 716-025
E-mail: chcchd@glide.net.in
Internet: http://www.infoexport.gc.ca/in

Consulate of Canada in Mumbai
4th Floor, 41-42 Maker Chambers VI
Jamnalal Bajaj Marg
Nariman Point
Mumbai (Bombay), 400021 India
Tel.: (91-22) 287-6027
Fax: (91-22) 287-5514
E-mail: mmbai@dfait-maeci.gc.ca
Internet: http://www.infoexport.gc.ca/in

Agriculture and Agri-Food Canada
Market and Industry Services Branch
Sir John Carling Building
930 Carling Ave.
Ottawa, ON K1A 0C5
Tel.: (613) 759-7744
Fax: (613) 759-7499
Internet: http://www.agr.gc.ca

Department of Foreign Affairs and International Trade
125 Sussex Dr.
Ottawa, ON K1A 0G2
Internet: http://www.dfait-maeci.gc.ca
Market Research Centre (TCM)
Tel.: (613) 996-3535
Fax: (613) 943-1103
Contact: Michelle Van Dyk, International Market
Research Officer
E-mail: michelle.van-dyk@dfait-maeci.gc.ca
Market Support Division (TCM)
Tel.: (613) 996-1431
Fax: (613) 944-0050
Contact: Patricia Filteau, Trade Commissioner
E-mail: patricia.filteau@dfait-maeci.gc.ca
Internet: http://www.infoexport.gc.ca
South Asia Division
Tel.: (613) 944-1653
Fax: (613) 996-5897
Contact: Alan McBride, Trade Commissioner
E-mail: alan.mcbride@dfait-macei.gc.ca

Canadian Food Inspection Agency
Office of Biotechnology
59 Camelot Dr.
Nepean, ON K1A 0Y9
Tel.: (613) 225-2342
Fax: (613) 228-6653
E-mail: cfiamaster@agr.gc.ca
Internet: http://www.inspection.gc.ca

Health Canada
International Affairs Directorate
Brooke Claxton Building, Room 814A
Postal Locator 0908A
Tunney's Pasture
Ottawa, ON K1A 0K9
Tel.: (613) 941-3136
Fax: (613) 952-7417
Internet: http://www.hc-sc.gc.ca

Industry Canada
Life Sciences Branch
PO Box 940, Station M
1505 Barrington St.
Halifax, NS B3J 2V9
Tel.: (902) 426-9958
Fax: (902) 426-2624
Contact: Mark Craig, Sector Officer
E-mail: craig.mark@ic.gc.ca
Internet: http://strategis.ic.gc.ca

Indian Government Contacts

High Commission of India in Canada
10 Springfield Rd.
Ottawa, ON K1M 1C9
Tel.: (613) 744-3751
Fax: (613) 744-0913
E-mail: hicomind@sprint.ca
Internet: http://www.docuweb.ca/India
Consulate General of India-Toronto
1835 Yonge St. (4th Floor)
Toronto, ON M4S 1X8
Tel.: (416) 960-0751
Fax: (416) 960-9812
Consulate General of India-Vancouver
325 Howe St. (2nd Floor)
Vancouver, BC V6C 1Z7
Tel.: (604) 662-8811
Fax: (604) 682-2471

Department of Agricultural Research and Education
Krishi Bhavan
Dr. Rajendra Prasas Rd-1
New Delhi, India
Tel.: (91-80) 338-2651
Fax: (91-11) 338-6004
Internet: http://dare.nic.in

Krishi Bhavan
Dr. Rajendra Prasas Rd-1
New Delhi, India
Tel.: (91-80) 338-2651
Fax: (91-11) 338-6004
Internet: http://dare.nic.in

Department of Biotechnology
Ministry of Science and Technology
Block 2, 6-8th Floor
CGO Complex, Lodi Road
New Delhi, 110003 India
Tel.: (91-11) 436-2950
Fax: (91-11) 436-2884
E-mail: btic@DBT.nic.in
Internet: http://dbtindia.nic.in

Block 2, 6-8th Floor
CGO Complex, Lodi Road
New Delhi, 110003 India
Tel.: (91-11) 436-2950
Fax: (91-11) 436-2884
E-mail: btic@DBT.nic.in
Internet: http://dbtindia.nic.in

Department of Scientific and Industrial  
Research (DSIR) Technology Bhavan
New Mehrauli Road
New Delhi, 110 016 India
Tel.: (91-11) 371-7063
Fax: (91-11) 371-0618
E-mail: dgcsir@csir.res.in
Internet: http://dsir.nic.in

Drug Controller General of India
Directorate General of Health Services
Nirman Bhawan
New Delhi, 110011 India
Tel.: (91-11) 301-8806
E-mail: dci@nb.nic.in

Directorate General of Foreign Trade
Ministry of Commerce and Industry
Udyog Bhavan
New Delhi, 110011 India
Tel.: (91-11) 301-1777
Fax: (91-11) 301-8613
Internet: http://dgft.delhi.nic.in

Ministry of Environment and Forests
Paryavaran Bhavan
CGO Complex, Lodhi Road
New Delhi, 110003 India
Tel.: (91-11) 436-1896
E-mail: secy@menf.delhi.nic.in
Internet: http://envfor.nic.in

Ministry of Health and Family Welfare
Nirman Bhavan
Maulana Azad Road
New Delhi, 110011 India
Tel.: (91-11) 301-8863
Fax: (91-11) 301-4252
Internet: http://mohfw.nic.in

National Pharmaceutical Pricing Authority
2E/21, Jhandewalan Extension, Link Road
New Delhi, 110055 India
Tel.: (91-11) 368-1982-86
Fax: (91-11) 368-2142
E-mail: nppa@hub.nic.in
Internet: http://nppaindia.nic.in

Key Indian Research Organizations

Centre for Cellular and Molecular Biology (CCMB)
Uppal Road
Hyderabad, 500007 India
Tel.: (91-40) 716-0222
Fax: (91-40) 716-0591
Internet: http://www.ccmb.res.in

Council of Scientific and Industrial Research (CSIR)
Anusadhan Bhavan, Rafi Marg
New Delhi, 110001 India
Tel.: (91-11) 371-0472
Fax: (91-11) 371-0618
E-mail: csirhq@sirnetd.ernet.in
Internet: http://sunsite.sut.ac.jp/asia/india/jitnet/csir

Indian Council of Agricultural Research (ICAR)

Krishi Bhawan
Dr. Rajendra Prasad Road
New Delhi, 110001 India
Tel.: (91-11) 338-2629
Fax: (91-11) 338-7293
E-mail: sm@icar.delhi.nic.in
Internet: http://www.icar.org.in
Note: Site includes links and addresses to all 27 National Research Centres and all 46 research institutes.

Indian Council of Medical Research (ICMR)
P.O. Box No. 4911
Ansari Nagar
New Delhi, 110029 India
Tel.: (91-11) 696-2895
Fax: (91-11) 686-8662
E-mail: icmrhqds@sansad.nic.in
Internet: http://www.icmr.nic.in/general.htm
Note: Site includes links and addresses to all Regional Medical Research Centres, Centres for Advanced Research and Permanent Research Institutes.

Tata Energy Research Institute (TERI)
Bioresources and Biotechnology Division
Darbari Seth Block, Habitat Place
Lodhi Road
New Delhi, 110003 India
Tel.: (91-11) 468-2100
Fax: (91-11) 468-2144
Internet: http://teriin.org/division/bbdiv/bbdiv.htm

Indian Associations

All India Biotechnology Association
"Vipps Centre" 2 Local Shopping Centre
Block-EFGH, Masjid Moth, G.K.-II
New Delhi, 110048 India
Tel.: (91-11) 648-1487
Fax: (91-11) 647-3089
E-mail: unmalik@aibaonline.com
Internet: http://www.aibaonline.com

Biotech Support Services
408 Archana Building, Sector 17
Vashi, Navi
Mumbai, 400705 India
Tel.: (91-22) 789-2431
E-mail: biotechinfo@rediffmail.com
Internet: http://www.biotechsupportindia.com

Confederation of Indian Industry
23, Institutional Area, Lodi Road
New Delhi, 110 003 India
Tel.: (91-11) 4629-9947
Fax: (91-11) 462-6149
Email: ciico@ciionline.org
Internet: http://www.ciionline.org/index.html

Indian Pharmaceutical Association
Kalina, Santacruz (East)
Mumbai, 400098 India
Tel.: (91-22) 612-2401
Fax: (91-22) 614-0480
Internet: http://www.indianpharma.org

Organisation of Pharmaceutical Producers of India
Cook's Building, 324 Dr. D.N. Road
Bombay, 400001 India
Tel.: (91-22) 204-5509
Fax: (91-22) 204-4705
E-mail: oppi@bom3.vsnl.net.in
Internet: http://www.indiaoppi.com
Cook's Building, 324 Dr. D.N. Road
Bombay, 400001 India
Tel.: (91-22) 204-5509
Fax: (91-22) 204-4705
E-mail: oppi@bom3.vsnl.net.in
Internet: http://www.indiaoppi.com

Canadian Biotechnology Associations

Ag-West Biotech
101 - 111 Research Dr.
Saskatoon, SK S7N 3R2
Tel.: (306) 975-1939
Fax: (306) 975-1966
E-mail: agwest@agwest.sk.ca
Internet: http://www.agwest.sk.ca

Alberta Biotechnology Association
1150, 10180 - 101 St.
Edmonton, AB T5J 3S4
Tel.: (780) 425-3815
Fax: (780) 423-3893
Contact: Myka Osinchuk, Executive Director
E-mail: myka@bioalberta.com
Internet: http://www.bioalberta.com

BioAtlantech
PO Box 636, Station A
Fredericton, NB E3B 5A6
Tel.: (506) 444-2444
Fax: (506) 444-5662
Contact: John Argall, Executive Director
E-mail: jargall@fundy.net
Internet: http://www.bioatlantech.nb.ca

BioEast
2nd Floor, Spencer Hall
220 Prince Philip Dr.
St. John's, NF A1B 3X5
Tel.: (709) 737-2682
Fax: (709) 737-4029
Contact: Margaret Miller, Managing Director
Internet: http://www.bioeast.ca

BIONova
c/o Innovacorp
101 Research Dr.
PO Box 790
Dartmouth, NS B2Y 3Z7
Tel.: (902) 424-8670
Fax: (902) 424-4679
Contact: Bill Mills, Executive Director
E-mail: bmills@innovacorp.ns.ca
Internet: http://www.bionova.ns.ca

Bio Quebec
6100 Mount Royal Ave.
Montreal, QC H4P 2R2
Tel.: (514) 733-8411
Fax: (514) 733-8272
E-mail: info@bioquebec.com
Internet: http://www.bioquebec.com

BIOTECanada
130 Albert St., Suite 420
Ottawa, ON K1P 5G2
Tel.: (613) 230-5585
Fax: (613) 563-8850
E-mail: info@biotech.ca
Internet: http://www.biotech.ca

British Columbia Biotechnology Alliance
3250 East Mall, Suite 225
Vancouver, BC V6T 1W5
Tel.: (604) 221-3020
Fax: (604) 221-3027
Contact: Paul Stinson, Executive Director
Internet: http://www.bcbiotech.ca

Canadian Agri-Food Research Council
Building 60, Heritage House
Central Experimental Farm
Ottawa, ON K1A 0C6
Tel.: (613) 234-2325
Fax: (613) 234-2330

Canadian Drug Manufacturers Association
4120 Young St., Suite 606
North York, ON M2P 2B8
Tel.: (416) 223-2333
Fax: (416) 223-2425
Internet: http://www.cdma-acfpp.org

Canadian Medical Association
1867 Alta Vista Dr.
Ottawa, ON K1G 3Y6
Tel.: (613) 731-9331
Internet: http://www.cma.ca

Canada's Research-Based Pharmaceutical Companies
302-1111 Prince of Wales Dr.
Ottawa, ON K2C 3T2
Tel.: (613) 727-1380
Fax: (613) 727-1407
Internet: http://www.canadapharma.org

Canadian Wholesale Drug Association (CDWA)
5255 Yonge St., Suite 505
Toronto, ON M2N 6P4
Tel.: (416) 222-3922
Fax: (416) 222-8960
Internet: http://www.cwda.com

Nonprescription Drug Manufacturers Association of Canada
1111 Prince of Wales Dr., Suite 406
Ottawa, ON K2C 3T2
Tel.: (613) 723-0777
Fax: (613) 723-0779
E-mail: ndmac@ndmac.ca
Internet: http://www.ndmac.org

Toronto Biotechnology Initiative
P.O. Box 446, Station A
Toronto, ON M5W 1C2
Tel.: (416) 392-4780
Fax: (416) 397-0906
Internet: http://www.torontobiotech.org

Ottawa Life Sciences Council
600 Peter Morand Dr., Suite 100
Ottawa, ON K1G 5Z3
Tel.: (613) 521-1008
Fax: (613) 521-3065
Internet: http://olsc.ca

References

Print

Asia Private Equity Review. "India Warms to Biotech," March 2002.

Canada Stockwatch. "MDS Inc.-MDS Sciex to Establish Research Centre in India," January 2001.

Confederation of Indian Industry. Status Paper: Biotechnology, 2001.

Channel News Asia. "India Struggles to Find its Niche in Biotech Research," March 2002.

Chaudhuri, Pramit Pal. "China Surges Ahead of India in Biotech Race," Hindustan Times, February 2002.

Computers Today. "Tapping Biotechnology for Business: The Indian Scenario," January 2002.

Dun & Bradstreet, Inc. Exporters' Encyclopaedia, "India," 2001.

Economic Times. "Biotech-Big Bucks Exist in Contract Research," January 2002.

-----. "Indian Companies Must Graduate in Drug Discovery Cycle," January 2002.

Financial Express. "India, Russia Joing Hands to Set Up Biotechnology Centre," December 2001.

-----. "Biotech Bodies Seek Rs17,000 Crore for 10th Plan R&D," February 2002.

-----. "Health Biotech Products Gain Ground in India," February 2002.

----. "Indian Biotech Sector to Touch Rs20 Billion by 2007," February 2002.

-----. "Dabur Sets Up Molecular Diagnostic Lab in Capital," April 2002.

Financial Times. "Monsanto Cautiously Optimistic on Indian Genetically Modified Cotton," March 2002.

Food Chemical News. "Indian Regulatory System Seen Stifling Biotechnology," February 2001.

Indian Business Insight. "Biotechnology and Informatics," December 2001.

-----. "Biotech-The Third Wave," January 2002.

-----. "Park to be Ready by 2003," February 2002.

-----. "India Becoming Hub for Drug Contract Research," March 2002.

Hector, Darlington Jose. "Biotech Major's Advice-Forget Park, Go For Research," Times of India, January 2002.

Herald, Deccan. "Sartorius Opens Knowledge Centre in Bangalore," Indian Business Insight, March 2002.

The Hindu. "India Poised for Giant Strides in Biotechnology," April 2001.

-----. "E&Y Taps India's Bio-Economy," February 2002.

-----. "Bangalore Bio to begin on April 15," March 2002.

-----. "Great Scope for Indian Companies in Biogeneric Drugs," March 2002.

MacKinnon, Ian. "An Industry in Embryo," Newsweek International, September 2001.

Madhavan, Narayanan. "India's Bangalore Aims to Capitalize on Genes," Reuters News, April 2001.

-----. "India Walks Gingerly Towards Biotech Dream," Reuters News, February 2002.

Mudur, Ganapati. "India Invests Heavily in Genomics Research," British Medical Journal, March 2001.

-----. "India to Tighten Rules on Human Embryonic Stem Cells Research," British Medical Journal, September 2001.

Nagaraj, Sudha. "Government Dichotomy in Stance on Life Form Patents," Economic Times, January 2002.

Najmi, Quaied and Bhanutej, N. "The New Sunrise: Biotechnology is the New Buzzword in the World of Science and Business," The Week, December 2001.

Press Trust of India. "India Testing GM seeds for rice, maize, tomato, cauliflower," December 2001.

-----. "India Needs an Intelligent Policy on GM Crops," January 2002.

-----. "India and Mauritius to Cooperate in Biotech," March 2002.

Raj, N. Gopal. "Biotech Research Company's Commercial Plans," The Hindu, April 2001.

Ramachandran, Hari. "India Allows Sowing of Three Gene Cotton Varieties," Reuters News, March 2002.

Reuters News. "Indian Drug Sales May Hit $25 billion by 2010," September 2001.

Shankar, Sitaraman. "Inda's Reliance Thinks Big in Biotech, Stem Cells," Reuters News, September 2001.

Sridharan, R. "Sir Richard Sykes, Chairman, GlaxoSmithKline, 'India will become attractive only when IPR is protected'," Business Today, February 2002.

The Statesman. "Biotechnology-the Next Growth Engine," September 2001.

Times of India. "Government to Harness Biotech Tools," September 2001.

-----. "Venture Funds to Help Small Biotech Firms," January 2002.

United States. United States Department of Commerce. "India Biotechnology-Agriculture," 2001.

-----. "India Biotechnology-Medical," 2001.

Vidal, John. "New Delhi Opens Door to GM Crops," The Guardian, March 2002.

Useful Internet Resources

Biotech Support Services: http://www.biotechsupportindia.com (Detailed information in the

biotechnology industry in India with contacts for government, industry and research centres.) Canada. Department of Foreign Affairs and International Trade: http://www.dfait-maeci.gc.ca

ExportSource: http://exportsource.gc.ca

India. Central Board of Excise and Customs: http://www.cbec.gov.in

India Image: http://www.nic.in (A gateway for Government of India information on the Web.)

Indian Initiative for Rice Genome Sequencing: http://www.genomeindia.org/index.html

InfoExport: http://www.infoexport.gc.ca

¹ The term "biotechnology" is used in a variety of ways by different countries and even those in the industry. Biotechnology can be divided into two stages of evolution: "traditional" biotechnology refers to processes including fermentation technology; "modern" biotechnology may be defined as the use of cellular and molecular processes to solve problems or make products. Statistics for the size and scope of the biotechnology industry do not typically indicate a definition and may also include support companies and peripheral companies including patent law firms and equipment suppliers. Most research on the Indian biotechnology market appears to use a broad definition of biotechnology and likely includes more traditional sectors and support services.

² All monetary amounts are expressed in Canadian dollars, unless otherwise indicated. The conversion rate to Canadian dollars is based on IDD Information Services, Tradeline, April 2002.

³ For contact information regarding key organizations mentioned in this report, see Key Contacts.